A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study


Abali H., YALÇIN Ş., Onal H. C., Dane F., Oksuzoglu B., ÖZDEMİR N., ...Daha Fazla

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.44, sa.7, ss.301-307, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 7
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1097/coc.0000000000000825
  • Dergi Adı: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.301-307
  • Anahtar Kelimeler: gastric, gastroesophageal, HER2, trastuzumab, gastrectomy, D2 dissection, SURGERY, CHEMOTHERAPY
  • Gazi Üniversitesi Adresli: Hayır

Özet

Background: Trastuzumab prolonged the overall survival in patients with advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression in combination with chemotherapy. In this phase II open-label prospective study, the tolerability and safety of trastuzumab with chemotherapy, and chemoradiotherapy for curatively resected patients with HER2-positive gastric carcinoma was investigated.